Extended indication Treatment of orthopoxvirus disease
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Tecovirimat
Domain Infectious diseases
Reason of inclusion New medicine (specialité)
Main indication Viral infections other
Extended indication Treatment of orthopoxvirus disease
Proprietary name Tpoxx
Manufacturer SIGA Technologies
Mechanism of action Other, see general comments
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Orthopoxvirus p37 protein inhibitor.

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Submission date October 2020
Expected Registration December 2021
Orphan drug Unknown
Registration phase Registration application pending
Additional remarks Tecovirimat is sinds 2018 geregistreerd door de FDA voor behandeling van pokken, waarbij een behandelduur van 14 dagen wordt aangehouden. Dit orale middel blokkeert het virale envelopeiwit P37, zodat er geen nieuwe infectieuze virussen vanuit geïnfecteerde cellen kunnen ontsnappen. Het is geregistreerd voor volwassenen en kinderen vanaf 13kg.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Dosage per administration 600 mg
References NCT02474589

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

References https://www.keionline.org/21725
Additional remarks In de Verenigde Staten wordt een prijs van $255 per dosis gevraagd.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information